cyrilzakka/clinical-trials huggingface dataset:
Apatinib and Chemotherapy Sequential Treatment With Cervical Cancer

The study is the single arm and single center clinical trials，We conduct the phase II clinical trial to further explore the efficacy and safety of Apatinib and chemotherapy sequential treatment with advanced recurrence of metastatic cervical cancer


Eligibility Criteria:
Inclusion Criteria:

* The pathological diagnosis of recurrent or metastatic cervical cancer;
* Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 1;
* Life expectancy of more than 3months;
* With normal marrow, liver and renal function：

  * blood routine examination ：HB≥90g/L，ANC ≥1.5×10\*9/L，PLT≥80×10\*9/L；
  * Biochemical examination: total bilirubin (TBil) of ≤1.5 upper normal limitation (UNL)，alanine aminotransferase (ALT) and aspartate aminotransferase (AST) of ≤2.5 UNL or ≤5 UNL ，acreatinine (Cr) of ≤ 1.25 UNL; creatinine clearance rate ≥ 45ml/min (Cockcroft-Gault);
* With written informed consent signed voluntarily by patients themselves .
* With good compliance and agree to accept follow-up of disease progression and adverse events.

Exclusion Criteria:

* Uncontrolled hypertension
* Suffered from grade II or above myocardial ischemia or myocardial infarction, uncontrolled arrhythmias
* With abnormal coagulation function， bleeding tendency or treating with thrombolysis and anticoagulation
* History of clinically relevant major bleeding event (e.g. gastrointestinal hemorrhage, bleeding ulcer, occult blood ≥ (++), and vasculitis) =\< 3 months prior to randomization;
* uncured the wound or fracture
* Centrally located tumors of local invasion of major blood vessels, or Researchers think that patients may invade the important blood vessels and cause fatal bleeding (CT or MRI);
* Factors affecting the oral medication (e.g. inability to swallow, chronic diarrhea and intestinal obstruction);
* Urine protein \>++, or urine protein in 24 hours\> 1.0g
* Accumulation of coelomic fluid (e.g. pleural effusion, ascites fluid, cardiac effusion) requiring treatment
* History of uncontrolled psychotropic drug abuse or mental disorders;
* Prior VEGFR inhibitor treatment ;
* Other malignancy within Before or at the same time other than basal cell skin cancer, or carcinoma in situ of the cervix;
Factorial Trial Investigating Outcome and Adherence Relevant Factors in an Online Self-help Intervention for Depression

A vast amount of studies show that online interventions are suitable to reduce symptoms of mental illness as for instance depression or anxiety. However, participants who use online interventions are more likely to drop out of treatment compared to face-to-face interventions. It is important to enhance adherence to online interventions so that participants engage longer in the programs. Also, as online interventions are useful to reduce the burden of mental illness, it is of interest to further improve outcomes of such interventions. Therefore, it will be investigated in this study whether or not four different factors have an impact in fostering adherence to and improving outcome of an internet-based self-help intervention based on problem-solving therapy. A multifactorial design will be used for this study to screen simultaneously whether or not i) a diagnostic telephone interview and, ii) an educational module based on motivational interviewing prior to the intervention and iii) guidance by the study team, and iv) automated e-mail reminders during the study are active factors in enhancing adherence to and outcome of online interventions.


Eligibility Criteria:
Inclusion Criteria:

* PHQ-9-Score between 5 - 14
* Signed Informed Consent
* Contact information provided in case of emergency
* Internet connection and device to use it (Smartphone, Computer, Tablet)
* Fluent in german language

Exclusion Criteria:

* Suicidal tendencies (SBQ-R \> 7)
* a current or previous diagnose of a bipolar or psychotic disorder
* a current diagnosis of severe depression or another psychological disorder
Use of Racotumomab in Patients With Pediatric Tumors Expressing N-glycolylated Gangliosides

This study will be carried out in children with diagnosis of cancer with tumors known to express N-glycolylated gangliosides. The disease must be resistant to conventional therapy. The acute toxicity and immune response will be evaluated.

The expression of N-glycolylated gangliosides in tumors has previously been investigated in the tumor sample bank at this Hospital. The expression of N-glycolyl GM3 was shown in neuroblastoma, Ewing's sarcoma, Wilm's tumor and retinoblastoma.

Gliomas and the aforementioned tumor types have a very bad prognosis when conventional treatment is ineffective.

New therapeutic strategies have thus been examined, and several immunotherapeutic approaches, including dendritic cell vaccines, peptide vaccines and anti-idiotype vaccines are currently being assessed.

Racotumomab is an anti-idiotype antibody capable of inducing anti-N-glycolyl GM3 antibodies in patients with melanoma, breast cancer and lung cancer.

Dose escalation studies have shown the safety of racotumomab in the 0.5 to 2 mg dose range. The 1 mg dose level was selected for the ensuing clinical studies.

This clinical trial in children involves three dose levels: 0.15 mg, 0.25 mg and 0.4 mg, owing to the difference in body surface between an adult (1.73 sq. m in average) and the candidate population for this study (0.55 to 0.7 sq. m).


Eligibility Criteria:
Inclusion Criteria:

* Children (both genders) of between 1 and 10 years old at the time of accrual.
* Diagnosis of neuroblastoma (progression after first line treatment), glioma (progressing disease or metastatic disease, without curative treatment options), Ewing's sarcoma (progressive metastatic disease to first line treatment or progressive disease to second line treatment), Wilm's tumor (metastatic relapse after treatment), or retinoblastoma (progressing disease or metastatic relapse during or after first line treatment).
* Previous cancer treatment finished 30 days before accrual.
* Lansky performance status over 50.

Exclusion Criteria:

* History of encephalopathy, convulsions, asthma or severe allergy.
* Infectious disease grade 3 or 4 according to CTCAE version 3.
* Hepatic, kidney or cardiac insufficiency.
* Marrow insufficiency after self-transplantation of hematopoietic stem cells.
* Weight inferior to 12 kg at the time of accrual.
* Concomitant cancer treatment.
* Inability to comply with study procedures.
A Study of Valganciclovir in the Treatment of Cytomegalovirus (CMV) Retinitis in Patients With AIDS

The purpose of this study is to see if valganciclovir is a safe treatment for CMV retinitis in patients who have been treated for this condition in the past. This study also examines the effectiveness of valganciclovir in preventing the recurrence of CMV retinitis.

Patients receive valganciclovir twice a day for 21 days as induction therapy then daily as maintenance therapy. Patients are encouraged to remain on study for at least 3 months and will remain until common study closure.

Eligibility Criteria:
Inclusion Criteria

Concurrent Medication:

Allowed with caution:

* Acyclovir.
* Famciclovir.
* Valaciclovir.
* Imipenem-cilastatin.
* Myelosuppressive agents.

Patients must have:

* HIV infection with CMV retinitis.
* Minimum of 4 weeks prior treatment with ganciclovir, foscarnet, or cidofovir.
* Intraocular implant in either or both eyes, as long as CMV retinitis is active in one eye, upon approval by Roche.

Exclusion Criteria

Co-existing Condition:

Patients with any of the following symptoms of conditions are excluded:

* Active extraocular CMV disease.
* Severe uncontrolled diarrhea or evidence of malabsorption.

Concurrent Medication:

Excluded:

* Foscarnet.
* Cidofovir.
* CMV hyperimmune globulin.
* Probenecid.

Patients with the following prior conditions are excluded:

* Ocular media opacities (corneal, aqueous, lens, or vitreous) preventing ophthalmologic retinal assessment.
* Simultaneous participation in another study (unless approved by Roche).

Required:

* A minimum of 4 weeks treatment with ganciclovir, foscarnet, or cidofovir.
* Approval required for prior use of investigational anti-CMV agents.
A Trial Investigating the Effect of Semaglutide on Hypoglycaemic Counterregulation Compared to Placebo in Subjects With Type 2 Diabetes

This trial is conducted in Europe. The aim of this trial is to investigate the effect of semaglutide on hypoglycaemic counter-regulation compared to placebo in subjects with type 2 diabetes.


Eligibility Criteria:
Inclusion Criteria:

* Subjects diagnosed with type 2 diabetes and on stable treatment for a period of 90 days prior to screening with metformin as monotherapy. Stable is defined as unchanged dose
* Male or female, age between18-64 years (both inclusive) at the time of signing informed consent
* Body Mass Index (BMI) between 20.0-35.0 kg/m\^2 (both inclusive)
* HbA1c (glycosylated haemoglobin) between 6.5-10.0% (both inclusive)

Exclusion Criteria:

* Treatment with any glucose lowering agent(s) other than metformin in a period of 90 days before screening. An exception is short-term treatment (less than or equal to 7 days in total) with insulin in connection with intercurrent illness
* Recurrent severe hypoglycaemia (more than 1 severe hypoglycaemic event during the last 12 months) or hypoglycaemic unawareness as judged by the investigator or hospitalisation for diabetic ketoacidosis during the previous 6 months
* Blood or plasma donation within the past month or more than 500 mL within the last 3 months prior to first semaglutide dosing
Translational Study of MSS, TP53 Mutation and Chromosome Instability Relationship in Endometrial Carcinoma

The objective is to understand the relationship between TP53 mutation, MSS and chromosome instability in endometrial cancer and the effect on clinical prognosis.We will collect a small amount of tumor tissue samples. NGS panel detection and WGD/AS analysis were performed on the tissue. Paracancer tissue was used as a negative control and relevant information in medical records during the operation. Then we will collect clinical diagnosis and disease information through telephone follow-up after the completion of the operation.

The test is sequenced using Illumina high-throughput sequencers and accompanying kits. Conduct preliminary quality control on the samples, and the tumor cell content of the tissue samples shall not be less than 30%. Tissue DNA was extracted from tumor tissue samples according to the instructions of the QIAGEN DNA extraction kit. Samples qualified for quality control shall be arranged for further library construction. The extracted DNA samples were sequentially purified by fragment purification, terminal repair, splicing, fragment size selection, PCR amplification, product purification, library enrichment, and library product quality control. After qualified quality control, the constructed library was sequenced by Illumina matching kit. Bioinformatics analysis would be conducted.

Eligibility Criteria:
Inclusion Criteria:

* willing to participate in the study and sign the informed consent
* age ≥18 years old
* researchers evaluated that it was suitable to participate in this translational study
* Endometrial cancer was confirmed histologically
* histopathological molecular classification was consistent with pMMR type and POLE wild type
* The tumor tissue obtained by operation was the primary lesion

Exclusion Criteria:

* Received chemotherapy within 14 days prior to sample collection, or received anti-tumor drug therapy such as radiotherapy, biotherapy, endocrine therapy, targeted therapy, immunotherapy, within 21 days prior to sample collection
* previously treated with KIF18A inhibitors
* researchers believed that the subjects were not suitable for the translational study for other reasons
Safety And Pharmacology Study Of SNX-5422 Mesylate In Subjects With Refractory Solid Tumor Malignancies

Hsp90 is a chemical in the body that is involved in promotion of cancer. SNX-5422 is an experimental drug that blocks Hsp90. It is being evaluated for safety and efficacy in patients with cancer.


Eligibility Criteria:
Inclusion Criteria:

* \>18 years old
* histologically confirmed solid tumor malignancy
* refractory to available therapy or for which no therapy is available
* adequate organ function

Exclusion Criteria:

* CNS malignancy
* significant GI disease
* at risk for prolonged QT interval
Hematoma Block for Reduction of Distal Radius Fractures

The purpose of this study is to Prove that injection of 15 to 20 mL of lidocaine 1% into the fracture site (Hematoma block) is more effective in terms of pain relieving then injection of 10 mL of lidocaine 2%, and equally safe in terms of complications, for closed reduction of distal radius fractures.


Eligibility Criteria:
Inclusion Criteria:

* Patients with Fractures of the distal radius, with or without ulna fracture

Exclusion Criteria:

* Children,
* pregnant women,
* patients with infection or suspected infection on the site for injection.
* Patients whose condition requires general anesthesia (patients with more fractures other than the distal radius and ulna, patients with many damage...)
Precision Clinical and Genetic Tools for Brain Health in Hemorrhagic Stroke

The overall goal of this study is to increase health care provider awareness for common risk factors and comorbidities in patients with hemorrhagic stroke that are related to impaired brain health, to ultimately improve patients management and associated outcomes. The specific objective is to test the performance and effectiveness of a custom electronic health record (EHR)-based notification module at time of index hospitalization and at follow-up for hemorrhagic stroke survivors, before disparities in access to outpatient care may limit opportunities to intervene.

The investigators hypothesize that notification of health care providers through the EHR will increase measurements of low-density lipoprotein (LDL) and glycated hemoglogbin A1c (HbA1c) and increase evaluation and management rates for obstructive sleep apnea and hearing impairment.


Eligibility Criteria:
Inclusion Criteria:

* Patients aged 18 years or older
* Presenting with a primary diagnosis of hemorrhagic stroke admitted to Massachusetts General Hospital inpatient stroke service

Exclusion Criteria:

* Patients not meeting above inclusion criteria
* Patients presenting with subdural or epidural hematoma
A Study of Rebif® in Subjects With Relapsing Multiple Sclerosis

This is an open-label, multi-center, 12-week, randomized, controlled, parallel group, Phase 4 study to assess whether the morning administration of interferon beta 1a (Rebif®) leads to a lower severity of flu-like symptoms (FLS) as compared to the evening administration, in subjects with relapsing multiple sclerosis (RMS).


Eligibility Criteria:
Inclusion Criteria:

* Males and females between 18 and 60 years of age
* Female subjects must be neither pregnant nor breast-feeding and must lack child-bearing potential. Furthermore, female subjects must not have been pregnant from at least three months prior to enter in the study
* Subjects have RMS according to the revised McDonald Criteria (2010)
* Subjects with an expanded disability status scale (EDSS) score of less than 6.0
* Subjects naive to treatment and eligible for treatment with Rebif® 44 three times a week, or patients having received glatiramer acetate with a wash-out from at least one month, or patients having received treatment with natalizumab or fingolimod with a wash-out from at least three months
* Subjects able to self-inject treatment using RebiSmart®
* Subjects willing and able to comply with the protocol for the duration of the study
* Subjects have given written informed consent to take part in the study

Exclusion Criteria:

* Subjects have any disease other than MS that could better explain his/her signs and symptoms
* Subjects who have received any immunosuppressive agents within 3 months prior to Baseline
* Subjects who have received any corticosteroids within 30 days prior to Baseline
* Subjects have a MS relapse within 30 days prior to Baseline
* Subjects have inadequate liver function and bone marrow reserve as defined in the protocol
* Subjects have moderate to severe renal impairment
* Subjects have any visual or physical impairment that precludes the subjects from self-injecting the treatment using RebiSmart®
* Subjects have hypersensitivity to natural or recombinant interferon, or to any of its excipients
* Subjects have any contra-indications to treatment with interferon (IFN) beta 1a according to Summary of Product Characteristics (SmPC)
* Subjects have any contra-indications to treatment with ibuprofen/paracetamol according to SmPC
* Obese subjects, defined by body mass index greater than 30 kilogram per square meter (kg/m\^2)
* Subjects have participated in any other investigational trial within 30 days from Baseline
* Subjects have any other significant disease that in the Investigator's opinion would exclude the subject from the trial
Effects of Fermented Milk Product Enriched With Plant Sterols and Policosanols in Mild Hypercholesterolaemic Adults

The objective of this study is to investigate the effect of consumption of a low-fat, no added sugar, dairy fermented product enriched with plant sterols and policosanols at two doses, on LDL-cholesterol concentration in hypercholesterolaemic adults after 3 weeks of product consumption versus active control product.


Eligibility Criteria:
Inclusion Criteria:

* male and female aged 20-75 years;
* BMI between 19 and 30 kg/m2 ,
* LDL-cholesterol plasma level between 130 mg/dL and 190 mg/dL (bounds included) stabilized for more than 3 months,
* without statin monotherapy or other hypocholesterolaemic drug treatment,
* accepting to follow the dietary recommendations advisable for hypercholesterolemic patient (NCEP-ATP III guidelines)

Exclusion Criteria:

* serum triglyceride (TG) levels ≥ 4 mmol/L (3.5 g/L), having experienced any cardiovascular event in the last 6 months,
* receiving systemic treatment or topical treatment likely to interfere with evaluation of the study parameters
Glaucoma Assessment Via Reading Ability

To explore a quantitative glaucoma evaluation tool of glaucoma through the dynamic evaluation of reading ability based on logarithmic Chinese reading acuity chart (C-READ), and investigate its feasibility.

Glaucoma is the most common cause of irreversible blindness in the world, and it's marked by the gradual loss of retinal ganglion cells and their optic nerve fibres. Early detection and treatment can successfully prevent the disease's development and prevent blindness. Glaucoma sufferers' near visual qualities, particularly their ability to read, might be compromised. Patients can, however, regain some comfortable reading capacity following glaucoma therapy. The logarithmic Chinese reading acuity chart (C-READ) can be beneficial as a tool for functional vision evaluation, and there is rising clinical interest in this well-standardized, calibrated reading chart. Reading chart standards that allow for equal assessment of reading factors such as acuity and speed are currently lacking. The C-READ approach as a judge of glaucoma patients' status lacks theoretical support, and functional visual evaluation tools are still in their infancy. Therefore, we want to complete these tasks: 1) develop a dynamic analytic system and improve the evaluation criteria for the C-READ testing procedure; 2) confirm the usefulness of C-READ for early glaucoma screening through clinical studies. C-READ will provide a reliable and cost-effective screening technique that is convenient, affordable, and noninvasive.

Eligibility Criteria:
Inclusion Criteria:

* Primary open angle glaucoma in at least 1 eye or labelled as a glaucoma suspect by a glaucoma specialist
* Age ≥18 years old
* with open angles on gonioscopy
* best-corrected visual acuity ≥0.5
* spherical refraction within ±5.0 diopters (D), and/or cylinder correction within 3.0 D

Exclusion Criteria:

* eyes with any evidence of physical abnormality of the iris or pupils on slit-lamp examination
* eyes with a history of trauma or inflammation
* undergone an intraocular surgery or laser within the previous 6 months/except uncomplicated cataract surgery
* using systemic or topical medications that could affect pupil responses, including pilocarpine or atropine
* presence of any media opacities that prevented good quality OCT or fundus images
* presence of any retinal or neurological disease other than glaucoma
* abnormal ocular motility that prevents binocular fixation (eg, nystagmus, strabismus)
* with severe systemic diseases or psychiatric disorders
The Effects of Cervical Mobilization on Cognitive Performance

Non spesific cervical pain syndromes are the most common cervical pathologies encountered in clinical practice. Non spesific cervical pain syndrome occurs as a result of postural deformities.

Massage and mobilization techniques are used in the treatment of Non spesific cervical pain syndrome due to their analgesic effects. The Cyriax mobilization technique is a manual therapy method applies to correct the limitation of movement in the joint and to relieve pain and functional disorders. Many studies have shown that Cyriax mobilization technique provides faster and momentary painless joint movement compared to other physical therapy modalities. Cervical mobilisation techniques also have regulator effect on autonomic nerve system. Cervical mobilisation also has positive effects on anxiety and tension.

In this study, 32 patients with age range 18-65 who applied to Kırşehir Ahi Evran University Training and Research Hospital were examined. The individuals included in the study were divided into two groups according to the paired randomization method. These groups were control and intervention groups. Traditional physiotherapy methods were applied to the control group, traditional physiotherapy and Cyriax mobilisation techniques were applied to the intervention group. Traditional physiotherapy methods were included; Transcutaneous Electrical Nerve Stimulation (TENS), Ultrasound (US), isometric strengthening exercises.

For the evaluation of patients; Visual Analogue Scale (VAS), cervical goniometric measurements, Lowett muscle test, Burdon Test and Beck Anxiety Test were used.

Eligibility Criteria:
Inclusion Criteria:

* Who had cervical pain longer than six weeks
* Getting at least five points from Neck Disability Index

Exclusion Criteria:

* Who had neck surgery,
* Who had traumatic spinal cord injury,
* Clinical diagnosis of radiculopathy,
* Clinical diagnosis of myelopathy (sensory or motor deficit),
* Clinical diagnosis of neurological or rheumatologic disease and structural scoliosis